Jul 14, 2026 8:00am EDT Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility
Jul 02, 2026 4:01pm EDT Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 12, 2026 4:01pm EDT Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity
Apr 07, 2026 8:00am EDT Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension
Apr 03, 2026 2:01pm EDT Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 26, 2026 4:01pm EDT Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity
Nov 20, 2025 9:54pm EST Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants
Nov 20, 2025 4:12pm EST Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Nov 20, 2025 4:01pm EST Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension
Nov 14, 2025 4:01pm EST Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity